Table 1.

Ongoing clinical trials involving patients with calcific aortic valve stenosis (CAVS).

Trial Name	NCT	Treatment	Phase	Population	Enrolment (No. of Patients)	Primary Outcome
EAVaLL	NCT02109614	Extended-release niacin vs. placebo	I	Aortic sclerosis or mild CAVS	238	Calcium score progression measured by cardiac CT at 2 years
	NCT03051360	PCSK9 inhibitor vs. placebo	II	Mild to moderate CAVS	140	Calcium score progression measured by cardiac CT and by NaF PET at 2 years
	NCT02481258	Ataciguat vs. placebo	II	Moderate CAVS	35	Changes in AV calcium levels at 6 months
SALTIRE II	NCT02132026	Alendronate/denosumab vs. placebo	II	Peak aortic jet velocity >2.5 m/s and grade 2–4 calcification of the AV on echocardiography	150	Change in AV calcium score at 6 months and 2 years
AVADEC	NCT03243890	Menaquinone-7 vs. placebo	-	AV calcification score above 300, but without clinical CAVS	389	Change in AV calcification at 2 years
BASIK2	NCT02917525	Vitamin K2 vs. placebo	II	Bicuspid AV and mild to moderate CAVS on prior echocardiography	44	Change in AV calcium metabolism measured by NaF PET at 6 months